• CXI Healthcare’s subsidiary Fujian Ying Sheng Huo Li Bioengineering posted FY2025/26 operating profit of KRW 5.88 billion, down 49.9%.
• Revenue fell 8.0% to KRW 49.52 billion.
• Net profit declined 47.9% to KRW 5.68 billion.
• Management cited an expired lease at the Wuyi Mountain cultivation base, plus lower output at the Pu’er tea plantation.
• The board set Oct. 8, 2026 as the decision date for the performance change disclosure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CXI Healthcare Technology Group Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008900670), on October 08, 2026, and is solely responsible for the information contained therein.